Organon 3Q 2026: Revenue $1.57B, Net income $164M, EPS $0.6— 10-Q Summary

What happened

Organon reported third-quarter 2026 revenue of $1.57B, down 1.7% from the prior year. Net income rose 2.5% to $164M, while diluted earnings per share, which means profit per share, fell to $0.6 from $0.61.

Confirmed

Global impact / market context

Lower revenue alongside higher net income means cost cuts or one-time items likely supported profit, not sales growth. Because earnings per share still slipped, investors see weaker profit per sale and may question whether Organon can grow without relying on expense reductions.

Analyst inference

Organon faces falling sales in older products like Nexplanon and Singulair, plus supply disruptions at a contract manufacturer that constrained international Established Brands. Growth from Hadlima and Emgality only partly offsets this, so the company is shifting toward biosimilars and new launches to replace lost revenue.

Analyst inference

What to watch

1. Watch whether disruptions at the contract manufacturer, facilities and logistics provider ease, since Organon says recovery efforts are continuing and these constraints hurt international Established Brands sales. Confirmed
2. Track the U.S. launch of Miudella, estimated for late 2026, because new product revenue could offset declines in older medicines if the launch proceeds on schedule. Proposed
3. Monitor whether biosimilar launches like Pyzchiva in Canada and Epyztek in Australia, expected in the first half of 2027, can replace falling sales from Nexplanon, Ontruzant and Singulair. Analyst inference

Evidence

• Original source link unavailable